Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyngenia Inc.

http://www.zyngenia.com

Latest From Zyngenia Inc.

BIO 2013 Tuesday Roundup: Reimbursement Reigns, Industry Innovation, New Antibodies

Our survey of news and notes from the second day of the BIO conference includes discussions of changes in the way pharma negotiates milestones, big ambitious projects to solve industry “dysfunction,” and a next-generation antibody developer pushing toward the clinic.

BioPharmaceutical Europe

Is The Time Finally Right For Bispecific Antibodies?

Merck, Lilly, Gilead and Celgene are among the companies striking deals that involve bispecific antibodies. The novel dual-acting drugs have been in development since the 1980s with little success, yet big pharma believes they may finally be coming of age.

Clinical Trials Platform Technologies

Start-Up Execs On The Move, July-August 2012

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Start-Up Execs On The Move, May 2012

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

Medical Device BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register